From October 20-22 along the banks of Shanghai's Huangpu River, the 2026 Sustainable Global Leaders Conference returns once again. Nobel Prize and Turing Award winners will take the stage to discuss the future and trends of technology, and the internet-famous professor who "rescues" people from anxiety and the era of involution—Macfarlane—will hold a live dialogue with Xiang Biao!
Limited seats available, first come first served. Let us join together for the sustainable appointment! [Click to register] Cathie Wood's ARK Invest released its trading records for October 14, showing that on that day it purchased 188,665 shares of AI cloud computing company CoreWeave, with a transaction value of approximately $14.68 million, making it the largest single increase of the day. Notably, CoreWeave's stock price fell 15.46% that day, yet ARK continued to add to its position. At the same time, ARK reduced its holdings in gene testing company Personal Genome Diagnostics by nearly $11 million, and bought shares in Meta and AI chip company Cerebras Systems, indicating it continues to adjust its positions in the technology and healthcare sectors.
Buying CoreWeave Against the Trend While Adding to Meta and Cerebras
ARK bought 188,665 shares of CoreWeave stock that day, with a transaction value of $14,680,023, continuing its recent trend of increasing its stake in this AI cloud computing infrastructure company. This transaction occurred at a time when AI-related stocks suffered a massive sell-off. CoreWeave's stock plunged 15.46% that day, as market concerns continued to escalate over returns on AI infrastructure investment and debt financing risks. In addition, ARK purchased 9,577 shares of Meta stock through the ARKW fund, worth approximately $7.3 million; and bought 44,689 shares of AI chip company Cerebras Systems, worth approximately $6.66 million. ARK also bought 500,457 shares of autonomous driving technology company Kodiak AI, worth approximately $850,000.
Reducing Holdings in Gene Testing and Software Companies, Selling About $6.56 Million of Palantir
On the selling side, ARK reduced its holdings in Personal Genome Diagnostics by 693,049 shares through the ARKG fund, with a transaction value of approximately $10.98 million, continuing its recent reduction of its position in the company. ARK also sold 113,555 shares of 10x Genomics through the ARKK fund, worth approximately $8.15 million, further cutting its holdings in some genomics companies. On the technology stock side, ARK sold 337,473 shares of restaurant payment and management software company Toast, worth approximately $10.42 million; reduced its holdings in Palantir by 31,432 shares, worth approximately $6.56 million; and also sold 25,605 shares of Shopify, worth approximately $4.52 million. At the same time, ARK slightly increased its holdings in biotech companies Freenome and Scribe Therapeutics, with transaction values of approximately $1.39 million and $8,776, respectively.
Overview of ARK's Main Trades
Direction: Buy, Company: CoreWeave, Shares: 188,665, Amount: $14.68 million. Direction: Sell, Company: Personal Genome Diagnostics, Shares: 693,049, Amount: $10.98 million. Direction: Sell, Company: Toast, Shares: 337,473, Amount: $10.42 million. Direction: Sell, Company: 10x Genomics, Shares: 113,555, Amount: $8.15 million. Direction: Buy, Company: Meta, Shares: 9,577, Amount: $7.3 million. Direction: Buy, Company: Cerebras Systems, Shares: 44,689, Amount: $6.66 million. Direction: Sell, Company: Palantir, Shares: 31,432, Amount: $6.56 million. Direction: Sell, Company: Shopify, Shares: 25,605, Amount: $4.52 million. Direction: Buy, Company: Freenome, Shares: 110,037, Amount: $1.39 million. Direction: Buy, Company: Kodiak AI, Shares: 500,457, Amount: $850,000.
Judging from the day's trades, ARK made clear position adjustments within the technology sector: on one hand, it continued to buy AI infrastructure-related companies such as CoreWeave, Meta, and Cerebras; on the other hand, it reduced holdings in Palantir, Shopify, and Toast, while also cutting some gene testing company positions. Among these, CoreWeave still received nearly $14.7 million in additional buying despite a 15.46% plunge in its stock price, making it the most noteworthy trade of the day.
Comments